secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001326732-24-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor posts Phase 2 data for vudalimab (PD1 x CTLA-4) in mCRPC
---------------------------------------------------------------

- Additional clinical data from Phase 2 study of vudalimab monotherapy in metastatic castration-resistant prostate cancer posted on website.
- Presentation includes vudalimab, a bispecific PD1 x CTLA-4 antibody, corporate overview.
- No specific efficacy/safety figures provided in the filing; refer to full presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000009/0001326732-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000009/xncr-20240306.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer